retatrutide parkinson's disease trial nct 💉𝗥𝗲𝘁𝗮𝘁𝗿𝘂𝘁𝗶𝗱𝗲'𝘀 𝗨𝗻𝗲𝘅𝗽𝗲𝗰𝘁𝗲𝗱 𝗦𝗶𝗱𝗲 𝗘𝗳𝗳𝗲𝗰𝘁: 𝗪𝗵𝗮𝘁 𝗬𝗼𝘂 𝗦𝗵𝗼𝘂𝗹𝗱 𝗞𝗻𝗼𝘄 𝗥𝗲𝘁𝗮𝘁𝗿𝘂𝘁𝗶𝗱𝗲: a new triple-agonist weight loss drug that is STILL IN CLINICAL TRIALS, is showing incredible results, with some Parkinson's disease drug therapies in

The duration of keeping the patch depends on the medication you are taking

36 Finally, a cross-sectional study also demonstrated adverse effects of GLP-1 agonists, with patients on exenatide reporting higher PHQ-9 scores (9.70 4.92 vs 6.70 4.66

Semaglutide (once weekly

Modified-release metformin is preferred over standard-release for tolerability and adherence

I would not recommend microdosing GLP-1s for individuals with significant amounts of weight to lose or known metabolic dysregulation. The bottom line is that there are still questions regarding the effectiveness and safety of microdosing GLP-1 medications, and this type of regimen is not for everyone

Now, when I inject something, I know its risky